ATE212231T1 - Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie - Google Patents
Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapieInfo
- Publication number
- ATE212231T1 ATE212231T1 AT95926883T AT95926883T ATE212231T1 AT E212231 T1 ATE212231 T1 AT E212231T1 AT 95926883 T AT95926883 T AT 95926883T AT 95926883 T AT95926883 T AT 95926883T AT E212231 T1 ATE212231 T1 AT E212231T1
- Authority
- AT
- Austria
- Prior art keywords
- tnf receptor
- steroid hormone
- combination therapy
- relates
- treatment
- Prior art date
Links
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 title abstract 2
- 239000003270 steroid hormone Substances 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 108050001326 26S Proteasome regulatory subunit 6A Proteins 0.000 abstract 1
- 102100029510 26S proteasome regulatory subunit 6A Human genes 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1995/002767 WO1997003686A1 (en) | 1995-07-14 | 1995-07-14 | Tnf receptor and steroid hormone in a combined therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE212231T1 true ATE212231T1 (de) | 2002-02-15 |
Family
ID=8166058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95926883T ATE212231T1 (de) | 1995-07-14 | 1995-07-14 | Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6225300B1 (de) |
| EP (1) | EP0839046B1 (de) |
| JP (1) | JP4011618B2 (de) |
| AT (1) | ATE212231T1 (de) |
| AU (1) | AU715260B2 (de) |
| DE (1) | DE69525181T2 (de) |
| DK (1) | DK0839046T3 (de) |
| ES (1) | ES2171547T3 (de) |
| IL (1) | IL118789A0 (de) |
| WO (1) | WO1997003686A1 (de) |
| ZA (1) | ZA965891B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7012060B1 (en) * | 1995-07-14 | 2006-03-14 | Applied Research Systems Ars Holding N.V. | TNF receptor and steroid hormone in a combined therapy |
| NL1006876C2 (nl) | 1997-08-28 | 1999-03-02 | Schiphol Luchthaven Nv | Platform voor het parkeren en afhandelen van vliegtuigen. |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| EP1450839A4 (de) * | 2001-11-06 | 2009-06-24 | Serono Lab | Verfahren zur behandlung von auf östrogen ansprechendem brustkrebs |
| US7674453B2 (en) | 2002-02-06 | 2010-03-09 | Ares Trading Sa | Tumor necrosis factor combined with interferon in demyelinating diseases |
| ES2304602T3 (es) | 2003-02-28 | 2008-10-16 | Ares Trading S.A. | Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| CA2100329C (en) * | 1991-01-18 | 2009-09-29 | David F. Carmichael | Methods for treating tumor necrosis factor mediated diseases |
| JPH07504203A (ja) * | 1992-09-15 | 1995-05-11 | イミュネックス・コーポレーション | 腫瘍壊死因子アンタゴニストを用いるtnf−依存性炎症の治療方法 |
| AU4719093A (en) | 1993-07-30 | 1995-02-28 | Kennedy Institute Of Rheumatology | Method for treating multiple sclerosis |
-
1995
- 1995-07-14 DK DK95926883T patent/DK0839046T3/da active
- 1995-07-14 AT AT95926883T patent/ATE212231T1/de not_active IP Right Cessation
- 1995-07-14 DE DE69525181T patent/DE69525181T2/de not_active Expired - Fee Related
- 1995-07-14 WO PCT/EP1995/002767 patent/WO1997003686A1/en not_active Ceased
- 1995-07-14 EP EP95926883A patent/EP0839046B1/de not_active Expired - Lifetime
- 1995-07-14 JP JP50619297A patent/JP4011618B2/ja not_active Expired - Fee Related
- 1995-07-14 AU AU31109/95A patent/AU715260B2/en not_active Ceased
- 1995-07-14 ES ES95926883T patent/ES2171547T3/es not_active Expired - Lifetime
- 1995-07-14 US US08/983,223 patent/US6225300B1/en not_active Expired - Fee Related
-
1996
- 1996-07-04 IL IL11878996A patent/IL118789A0/xx not_active IP Right Cessation
- 1996-07-11 ZA ZA965891A patent/ZA965891B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2171547T3 (es) | 2002-09-16 |
| DE69525181D1 (de) | 2002-03-14 |
| DE69525181T2 (de) | 2002-08-14 |
| IL118789A0 (en) | 1996-10-31 |
| AU715260B2 (en) | 2000-01-20 |
| DK0839046T3 (da) | 2002-02-18 |
| ZA965891B (en) | 1997-03-19 |
| EP0839046B1 (de) | 2002-01-23 |
| WO1997003686A1 (en) | 1997-02-06 |
| JPH11509213A (ja) | 1999-08-17 |
| US6225300B1 (en) | 2001-05-01 |
| AU3110995A (en) | 1997-02-18 |
| EP0839046A1 (de) | 1998-05-06 |
| HK1009403A1 (en) | 1999-06-04 |
| JP4011618B2 (ja) | 2007-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA37259C2 (uk) | Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч | |
| EA200201000A1 (ru) | Гормон-заместительная терапия | |
| MD1920F2 (ro) | Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer | |
| PT748190E (pt) | Metodos e formulacoes para uso no tratamento de disturbios ginecologicos benignos | |
| NZ324500A (en) | Humanized antibodies to human gp39, compositions containing and therapeutic use thereof | |
| MY131522A (en) | PHARMACEUTICAL COMPOSITION AND USES FOR ANDROST-5-ENE-3ß,17ß-DIOL | |
| DE60040753D1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
| EA200600964A1 (ru) | Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина | |
| ATE217192T1 (de) | Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen | |
| NO20003546L (no) | Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse | |
| YU69000A (sh) | Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe | |
| AU3254395A (en) | Use of a combination product that contains a competitive progesterone antagonist and a gestagen for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri | |
| TR199802705T2 (xx) | Progestojen-anti-progestojen k�r� | |
| EP0902789A4 (de) | ||
| DK1392329T3 (da) | Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom | |
| WO2006053172A3 (en) | The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases | |
| CA2454339A1 (en) | Methods for preventing antipsychotic-induced weight gain | |
| BR9710566A (pt) | M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio | |
| AU2732597A (en) | Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs | |
| CA2504697A1 (en) | Methods for treating migraine | |
| EP0663835A1 (de) | Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft. | |
| DE69525181D1 (de) | Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie | |
| KR960030947A (ko) | src SH2 특이성 화합물의 골흡수 질환 치료 용도 | |
| CA2459033A1 (en) | Methods for inhibiting cognitive deterioration in adults with down's syndrome | |
| CA2258177A1 (en) | 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |